Key facts
- Notable investors include Charlottesville Angel Network, Cville BioHub, National Science Foundation Innovation Corps Program.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for SalivIQ
- ·The full record, as it builds
Funding rounds
No funding rounds for SalivIQ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SalivIQ
Developer of saliva-based molecular diagnostic tests designed for the development of accurate diagnostics. The company offers a revolutionary, non-invasive way to detect strep throat with accuracy in minutes, ensuring patients avoid the discomfort of a throat swab and receive the correct, timely medical treatment, which prevents the overuse of antibiotics and unnecessary follow-up testing, enabling customers to confidently make accurate and appropriate diagnostic decisions right at the point-of-care by improving patient experience and clinical outcomes.
- Sector
- Healthcare
- HQ
- Harrisonburg, VA, United States
- Founded
- 2024
- Employees
- 2
- Website
- saliviqdiagnostics.com/
- Ownership
- Privately Held (backing)
SalivIQ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SalivIQ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SalivIQ in its N-PORT filings yet. We sweep new filings monthly.